Anti‐CD4 and anti‐CD8 neutralizing antibodies were administered to evaluate how CD4+ T or CD8+ T influenced the tumor‐promoting effects of Plac1 expression (Figure 5E, Figure S9H–I, Supporting Information). Here, CD8A is linked to neoplasm.